Desmond Chin

Principal Scientist @Novo Nordisk

Cambridge, MA, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Dec 2024 — Present

Principal Scientist @Novo Nordisk

View department →

Boston, MA, US

Built and led translational teams supporting multiple programs: designed and qualified PD, target engagement, and exploratory biomarker assays across murine/NHP models and clinical samples, encompassing matrix stability, interference testing, and multi-species qualification.Led biomarker strategies for multiple programs in diabetes and rare blood diseases, with biomarkers spanning target engagement, proof-of-mechanism/concept, and exploratory biomarkers across discovery through Phase 2.Developed precision medicine hypotheses by mining large-cohort datasets (UK Biobank) and registered clinical trials to identify predictive biomarkers enabling patient subpopulation enrichment strategies.Established feasibility of bioimaging biomarkers (dopamine PET, MRI, electroencephalogram) as Go/No-Go decision criteria for Phase 1; integrated imaging readouts to derisk target and candidate selection.Shaped Phase 1 clinical trial design by integrating PKPD modeling to inform initial dose/frequency and propose biomarker-driven decision-guiding framework in collaboration with Clinical Pharmacology and Biostatistics.Served as translational lead for a Phase 2 trial in lower-risk MDS (NCT05••••25): designed the full exploratory biomarker plan, directed CRO oversight, qualified molecular assays, compiled central lab manuals, and presented interim findings to the Medical Director and at cross-functional global science meetings.(manuscript in preparation)

EDUCATION

2008 — 2011

Nanyang Technological University Singapore

Bachelor of Science (BSc) Biological Science, Biology, General

2011 — 2015

National University of Singapore

Doctor of Philosophy (PhD), Cancer Biology

SKILLS

BiochemistryFlow CytometryCell CultureProtein ExpressionCell BiologyMolecular BiologyWestern BlottingHplcBiotechnology

ABOUT DESMOND CHIN

10 years of experience in drug development spanning multiple disease indications such as hemoglobinopathies, cardiometabolic diseases, oncology, and bleeding disorders. Experienced translational science leader in biomarker strategy and executions for programs from ranging from target validation to phase I clinical trials, and product lifecycle management.3. Effective manager who has successfully led internal cross-functional teams and managed external CROs to achieve company goals.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Desmond Chin — Principal Scientist at Novo Nordisk in Cambridge, MA, US | Unifers